Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021
- Paul-Ehrlich-Institut follows the FDA in giving clearance to begin a Phase I/IIa trial of HDP-101; first trial centers initiated in the USA
- Gross issue proceeds of over EUR 20 million generated from private placement in June
- Significant advances made in partner projects
- Guidance revised
Heidelberg Pharma AG today reported on the first nine months of fiscal year 2021 (1 December 2020 – 31 August 2021) and the Group’s financial figures.
Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: “We are delighted to have achieved important milestones in recent weeks and to have cleared several organizational hurdles for our initial clinical trial of HDP-101. The first two trial centers were initiated recently, and we are now eagerly awaiting the inclusion of the first patient.